文献速递白血病造血干细胞移植与细胞治疗

多中心研究:移植后低剂量奥加伊妥珠单抗预防急性淋巴细胞白血病复发

A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2024-01-01

这项1期多中心研究评估了异基因造血干细胞移植后低剂量奥加伊妥珠单抗(INO)预防CD22阳性急性淋巴细胞白血病(ALL)复发的安全性和可行性。18例高危患者在移植后第40至100天接受INO治疗,最常见毒性为血小板减少,未发生窦状隙阻塞综合征,最大耐受剂量为0.6 mg/m2,1年无进展生存率和总生存率分别为89%和94%。

要点

  • 移植后低剂量INO的最大耐受剂量为0.6 mg/m2,未发生窦状隙阻塞综合征。
  • 最常见毒性为血小板减少,1年非复发死亡率为5.6%。
  • 中位随访18.1个月,1年无进展生存率和总生存率分别为89%和94%。

核心结论

  • 低剂量INO具有良好的安全性特征,并与较高的1年无进展生存率相关。

研究设计与样本

  • 多中心1期试验,采用「3+3」剂量递增模型,纳入18例接受异基因造血干细胞移植后达到完全缓解的高危CD22阳性ALL患者。
  • 患者年龄16至75岁,移植后第40至100天入组,中位年龄44岁(范围17-66岁),移植时首次完全缓解14例,第二次或以上完全缓解4例。
  • 72%的患者接受了减低强度预处理方案。

主要发现

  • 最常见毒性为血小板减少,未发生窦状隙阻塞综合征,最大耐受剂量为0.6 mg/m2。
  • 1年非复发死亡率为5.6%。
  • 中位随访18.1个月(范围8.6-59个月),移植后1年无进展生存率和总生存率分别为89%和94%。

关键数值与推荐

  • 剂量水平为0.3 mg/m2、0.4 mg/m2、0.5 mg/m2和0.6 mg/m2,于28天周期的第1天给药。
  • 最大耐受剂量为0.6 mg/m2。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The curative potential of allogeneic hematopoietic transplantation (allo-HCT) in patients with acute lymphoblastic leukemia (ALL) is hampered by relapse. Inotuzumab ozogamicin (INO) is an anti-CD22 monoclonal antibody bound to calicheamicin, which has significant activity against ALL. We hypothesized that low-dose INO would be safe and feasible after allo-HCT. Therefore, we conducted a phase 1 study to determine the dose and safety in this setting. Patients were eligible if they were aged 16 to 75 years, had undergone allo-HCT for CD22+ ALL, were in complete remission (CR) after allo-HCT, had high risk of recurrence, were between day 40 and 100 after allo-HCT with adequate graft function, and did not have a history of sinusoidal obstruction syndrome (SOS). The objectives of this trial were to define INO maximum tolerated dose (MTD), to determine post-allo-HCT INO safety, and to measure 1-year progression-free survival (PFS). The trial design followed a "3+3" model. The treatment consisted of INO given on day 1 of 28-day cycles. Dose levels were 0.3 mg/m2, 0.4 mg/m2, 0.5 mg/m2, and 0.6 mg/m2. Median age was 44 years (range, 17-66 years; n = 18). Disease status at transplantation was first CR (n = 14) or second CR or beyond (n = 4). Preparative regimen was of reduced intensity in 72% of patients who received transplantation. Most common toxicity was thrombocytopenia. There were no instances of SOS; the MTD was 0.6 mg/m2. One-year nonrelapse mortality was 5.6%. With a median follow-up of 18.1 months (range, 8.6-59 months) 1-year post-allo-HCT PFS and overall survival is 89% and 94%, respectively. Low-dose INO has a favorable safety profile and was associated with high rates of 1-year PFS. This trial was registered at www.clinicaltrials.gov as #NCT03104491.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Metheny LL, Sobecks R, Cho C, et al. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia. Blood Adv. 2024. PMID: 38170741. doi:10.1182/bloodadvances.2023011514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。